Resmetirom for the treatment of nonalcoholic steatohepatitis: Evaluating the robustness of available evidence

Dig Liver Dis. 2024 Jun;56(6):1117-1118. doi: 10.1016/j.dld.2024.03.009. Epub 2024 Mar 29.

Authors

Stefano Ciardullo¹, Alessandro Mantovani²

Affiliations

¹ Department of Medicine and Rehabilitation, Policlinico di Monza, Monza, Italy; School of Medicine and Surgery, University of Milano Bicocca, Milan, Italy. Electronic address: stefano.ciardullo@unimib.it.
² Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.

PMID: 38555197
DOI: 10.1016/j.dld.2024.03.009

No abstract available

Publication types

Letter

MeSH terms

Humans
Non-alcoholic Fatty Liver Disease* / drug therapy
Non-alcoholic Fatty Liver Disease* / therapy
Randomized Controlled Trials as Topic